Roche’s CellCept Gains “Black Box” Warning On Use During Pregnancy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reinforces warning on increased risk of miscarriage, congenital deformities in light of postmarketing data from Roche, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.
EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
GSK to supply additional data for breast cancer drug; panel okays generics for Roche’s CellCept.